Compared with healthy breastfed infants, the gut microbiota of infants with CMA is often out of balance.6-10 This imbalance (dysbiosis) is typically characterised by:


Lower levels of beneficial Bifidobacteria7,8

 

Higher levels of adult-like bacteria such as Clostridia and Eubacteria6,7,9

A balanced gut microbiota is important for the development of the immune system.11-13

Breastmilk is the best source of nutrition for infants with CMA.14,15 It contains prebiotic oligosaccharides and beneficial bacteria that support the development of a balanced gut microbiota.16,17

Synbiotics are a combination of prebiotics and beneficial bacteria (probiotics) that work synergistically together.18

For formula-fed infants with CMA, over 10 years of research with allergic infants has shown the benefits of supplementing hypoallergenic formula with synbiotics.*6,10,19-26


Well-tolerated10,19,20


Rebalances the gut microbiota6,10,21-24


Supports normal growth10,19-22


Improved clinical outcomes vs non- synbiotic formulas20,22,24-26

Randomised controlled trials

van der Aa 201024

12-week RCT of infants with AD (n=90)

Compared to an EHF without synbiotics, those in the synbiotic EHF group showed:

  • A gut microbiota closer to that of a healthy breastfed infant
  • Reduced constipation (p=0.01) and dry stools (p=0.001)
  • Reduced AD severity* (p=0.04)

van der Aa 201125

Follow-up from 12-week RCT of infants with AD (n=75)

Compared to an EHF without synbiotics, those in the synbiotic EHF group showed:

  •  A significantly lower prevalence of asthma-like symptoms at one-year follow-up (p=0.04)
  • Significantly less asthma medication use at one-year follow-up (p=0.02)

Systematic review

Sorensen 202122

Meta-analysis of four RCTs of infants with CMA (n=410)

Compared to an AAF without synbiotics, a synbiotic AAF supported:

  • A gut microbiota closer to that of a healthy breastfed infant
  • Fewer infants with infections (p=0.001)
  • Lower overall medication use (p<0.001)
  • Fewer hospital admissions due to infection (p=0.036)
  • Potential healthcare cost savings

Cohort studies

Sorensen 202126

Retrospective matched cohort study of infants with CMA using data from the THIN GP database (n=148)

Compared to an AAF without synbiotics, a synbiotic AAF was associated with:

  • Fewer GI, skin and/or respiratory symptoms* (p<0.001)
  • A lower rate of dietitian contacts (p=0.014)
  • Lower rates of infections (p<0.001) and medication prescriptions (p<0.001)
  • A shorter clinical journey† (p<0.001)
  • Potential healthcare cost savings

Hubbard 202220

Single-arm, prospective study of infants with non-IgE CMA (n=29)

Compared to EHFs without synbiotics*, a synbiotic EHF supported:

  • Reduced incidence and severity of constipation, abdominal discomfort and wind (p<0.05)
  • Reduced rhinitis severity and itchy eyes (p<0.05)
  • Reduced AD severity† (p=0.03)
  • A lower mean number of hospital visits and medication prescriptions in the 6 months after initiation‡ (p<0.05)
  • Improved caregiver quality of life scores# (p=0.004)

Discover the only hypoallergenic formula range with synbiotics*†

Neocate Syneo

The only amino acid formula to contain synbiotics*

Learn more

Aptamil Pepti Syneo

The only extensively hydrolysed formula to contain synbiotics*

Learn more

*Synbiotic blend: Bifidobacterium breve M-16V (probiotic) & short and long-chain galacto- and/or fructo-oligosaccharides (prebiotic).

AAF: Amino Acid-based Formula; AD: atopic dermatitis; CMA: Cow’s Milk Allergy; EHF: Extensively Hydrolysed Formula; FAQL-PB: Food Allergy Quality of Life-Parental Burden; GI: gastrointestinal; HCP: healthcare professional; PO-SCORAD: Patient‐Orientated SCORing AD; RCT: Randomised Controlled Trial; THIN: The Health Improvement Network

van der Aa 201024: *Subgroup of n=48 infants with IgE associated AD.

Sorensen 202126: *Diarrhoea, constipation, flatulence, vomiting, reflux, bloody stools, mucus in stools, colic, eczema & urticaria. †Clinical journey endpoint measured as being asymptomatic and not requiring a hypoallergenic formula prescription for at least 3 months.

Hubbard 202220: *Baseline non-synbiotic formula (n=27 out of n=29 well-established on a non-synbiotic EHF). †Significant reduction in PO-SCORAD in subgroup of n=6 infants with more severe AD at baseline.

‡Follow-up arm of study n=13. #Assessed via FAQL-PB questionnaire.

1. Luyt, et al. Clin Experimental Allergy. 2014;44(5):642-72.

2. Meyer, et al. Pediatr Allergy Immunol. 2018;29(7):689-704.

3. Fox, et al. Clin Transl Allergy. 2019;9:40.

4. Koletzko, et al. JPGN. 2012;55(2):221-9.

5. Grimshaw, et al. Clin Transl Allergy. 2016;6:1.

6. Candy, et al. Pediatr Research. 2018;83(3):677-86.

7. Canani, et al. ISME J. 2016;10(3):742-50.

8. Harmsen, et al. JPGN. 2000;30(1):61-7.

9. Thompson- Chagoyan, et al. Pediatr Allergy Immunol. 2010;21:e394-400.

10. Burks, et al. Ped Allergy Immunol. 2015;26(4):316-22.

11. Martin, et al. Benef Microbes. 2010;1(4):367-82.

12. West, et al. J Allergy Clin Immunol. 2015;135(1):3-13.

13. Wopereis, et al. Pediatr Allergy Immunol. 2014;25(5):428-38.

14. WHO. Infant and  young child feeding, 2003.

15. Vandenplas, et al. J Asthma Allergy. 2021;14:1243-56.

16. Moossavi, et al. Front Pediatr. 2018;6:197.

17. Boehm, et al. J Nutr. 2007;137(3Suppl.2):847S-9S.

18. Pandey, et al. J Food Sci Technol. 2015;52(12):7577-87.

19. Harvey, et al. Pediatr Res. 2014;75(2):343-51.

20. Hubbard, et al. Immun Inflamm Dis. 2022;10(6):e636.

21. Abrahamse-Berkeveld, et al. J Nutr Sci. 2016;5:e42.

22. Sorensen, et al. Nutrients. 2021;13(3):935.

23. Fox, et al. Clin Transl Allergy. 2019;9:5.

24. van der Aa, et al. Clin Exp Allergy. 2010;40(5):795-804.

25. van der Aa, et al. Allergy. 2011;66(2):170-7.

26. Sorensen, et al. Nutrients. 2021;13(7):2205.

27. Kinnear, et al. 2021 HCP & parent survey – AAF + synbiotics, Poster presentation at the 8th International Conference on Nutrition & Growth conference, accepted May 2021. 
28. Data on file. 2023 Neocate Syneo and Pepti Syneo experience survey. Parent survey, n=90 parents, HCP survey n=120 HCPs. Jan 2023.
29. Market comparison of UK EHF and AAF data cards, September 2023.

 

Accurate at publication: October 2023

 

Nutricia offers access to a wide range of support services and resources including:

  • • Our free Sampling Service to order product samples and have them sent to your patients' homes.
  • • A range of CPD accredited e-learning programmes.
  • • Order free paper copies of our support tools for yourself or to use with your patients.
  • • Sign up to receiving marketing communications and be the first to know about our free educational events & webinars, the latest scientific research and product updates.
Register today for free

 

Help us provide information most relevant to you

Please ensure your role and areas of interest are up to date.

Update profile
  • Nutricia Limited is a company registered in England and Wales with company number 00275552. VAT Number GB436975115
  • © 2024 Nutricia. All rights reserved.
x